16th International Cardiovascular Research Meeting

Miejsce:

Online

Data:

5-7 października 2023 14:00

16th International Cardiovascular Research Meeting (ICVRM)
The ELECTRA-SIRIO 2 Investigators Meeting

Conference under the auspices of GREAT International Network
Bydgoszcz 5-7th October 2023

Panel klienta

PROGRAM MERYTORYCZNY

Zapraszamy do zapoznania się ze szczegółami programu.

Transmisja

14:00 - 14:10

Opening speech

Jacek Kubica (Poland)

14:10 - 14:30

Lecture of the day: Not Everything That Glitters is Gold, Even When Randomised

Marc P. Bonaca (USA)

14:30 - 15:45

Session 1: Sesja badania ELECTRA – SIRIO 2

Chairpersons: Stefano De Servi, Eliano P. Navarese, Wojciech Wojakowski, Jacek Kubica

14:30 - 14:45

Presentation, care and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology

Andrzej Budaj (Poland)

14:45 - 15:00

Timing of coronary angiography in patients with non-ST-elevation acute coronary syndrome: long-term clinical outcomes from the nationwide SWEDEHEART registry

Stefan K James (Sweden)

15:00 - 15:15

Stepwise relationship between delay to percutaneous coronary intervention and long-term mortality in patients with non-ST-segment elevation myocardial infarction

Kamil Bujak (Poland)

15:15 - 15:30

GRACE scores or high-sensitivity troponin for timing of coronary angiography in non-ST-elevation acute coronary syndromes

Holger Thiele (Germany)

15:30 - 15:45

Discussion

15:45 - 16:00

Break

16:00 - 17:15

Session 2: Sesja badania ELECTRA – SIRIO 2

Chairpersons: Diana A. Gorog, Stefan K. James, Piotr Adamski

16:00 - 16:15

Should aspirin be stopped at day 0 after PCI?

Paul A Gurbel (USA)

16:15 - 16:30

Continue or discontinue aspirin before non-cardiac surgery?

Tobias Geisler (Germany)

16:30 - 16:45

Short DAPT for PCI after CABG: ready for prime time.

Jolanta M Siller-Matula (Austria)

16:45 - 17:00

Current challenges for treatment of older patients with acute coronary syndrome

Stefano De Servi (Italy)

17:00 - 17:15

Discussion

17:15 - 17:30

Break

17:30 - 18:45

Session 3: Sesja badania ELECTRA – SIRIO 2

Chairpersons: Jolanta M. Siller-Matula, Tobias Geisler, Zuzana Motovska, Małgorzata Ostrowska

17:30 - 17:45

HeartLogic - a new research tool

Matteo Pavoni (Italy)

17:45 - 18:00

How to advance from translational researches to randomized clinical trials?: Experiences from the K-DAPT society

Young-Hoon Jeong (South Korea)

18:00 - 18:15

Effectiveness of lower maintenance dose of ticagrelor one month after myocardial infarction. The Randomized multicenter, international, double-blind Clinical Trial. Rationale, protocol and current status of the ELECTRA SIRIO 2 trial.

Jacek Kubica (Poland)

18:15 - 18:30

Comparison of de-escalation of DAPT intensity or duration in patients with ACS undergoing PCI

Diana A Gorog (United Kingdom)

18:30 - 18:45

Discussion

18:45 - 19:00

Break

19:00 - 20:15

Session 4: Sesja badania ELECTRA – SIRIO 2

Chairpersons: Gavino Casu, Robert Gil, Marek Gierlotka, Piotr Niezgoda
session sponsored by the Ferrer company

19:00 - 19:15

Cangrelor for comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention: the CANGRELOR-OHCA study.

Marko Noc (Slovenia)

19:15 - 19:30

Dual antiplatelet therapy for shock patients with acute myocardial infarction (DAPT-SHOCK-AMI) trial

Zuzana Motovska (Czech Republic)

19:30 - 19:45

Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.

Bernd Jilma (Austria)

19:45 - 20:00

Cangrelor in high risk ST-segment elevation myocardial infarction patients treated with primary Percutaneous Coronary Interventions (CHRONOS PCI) study

Jacek Kubica (Poland)

20:00 - 20:15

Discussion

14:00 - 14:10

Summary of Day 1

Eliano P Navarese (Italy)

14:10 - 14:30

Lecture of the day: Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond

Nabil G Seidah (Canada)

14:30 - 15:45

Session 5

Chairpersons: Miłosz Jaguszewski, Piotr Adamski

14:30 - 14:45

Independent Causal Effect of Remnant Cholesterol on Atherosclerotic Cardiovascular Outcomes: A Mendelian Randomization Study.

Eliano P. Navarese (Italy)

14:45 - 15:00

Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy - a subanalysis of the ODYSSEY APPRISE study

Maciej Banach (Poland)

15:00 - 15:15

Dietary management of patients at high risk for cardiovascular disease; EUROASPIRE V

Piotr Jankowski (Poland)

15:15 - 15:30

National Trends in Statin Use in Lithuania from 2010 to 2021

Jolita Badariene (Lithuania)

15:30 - 15:45

Discussion

15:45 - 16:00

Break

16:00 - 17:00

Session 6

Chairpersons: Wiktor Kuliczkowski, Marko Noc, Agnieszka Tycińska, Tomasz Fabiszak

16:00 - 16:15

Out-of-hospital cardiac arrest: Do we have to perform coronary angiography?

Wojciech Wańha (Poland)

16:15 - 16:30

Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC

Marek Gierlotka (Poland)

16:30 - 16:45

Pharmacokinetics, pharmacodynamic and repetitive use of levosimendan

Grzegorz Grześk (Poland)

16:45 - 17:00

Discussion

17:00 - 17:15

Break

17:15 - 18:15

Session 7

Chairpersons: Jarosław Kaźmierczak, Łukasz Szarpak, Małgorzata Ostrowska

17:15 - 17:30

Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the EuroBifurcation Club registry

Robert Gil (Poland)

17:30 - 17:45

Trends in major adverse cardiac events and healthcare utilization during the COVID-19 pandemic in Alberta, Canada

Paolo Raggi (Canada)

17:45 - 18:00

Determinants of anti-SARS-CoV-2 antibodies after vaccination in kidney transplant recipients

Magdalena Krintus (Poland)

18:00 - 18:15

Discussion

18:15 - 18:30

Break

18:30 - 19:30

Session 8

Chairpersons: Piotr Jankowski, Maciej Lesiak, Sławomir Dobrzycki, Piotr Niezgoda

18:30 - 18:45

An update on novel therapies for treating patients with arterial thrombosis

Udaya S Tantry (USA)

18:45 - 19:00

COVID-19-induced coagulopathy - Experience, achievements, prospects.

Łukasz Szarpak (Poland)

19:00 - 19:15

Altered platelet reactivity, coagulation, endothelial and inflammatory markers early after smoking cessation

Bogumił Ramotowski (Poland)

19:15 - 19:30

Discussion

09:20 - 09:30

Summary of Day 2

Piotr Adamski (Poland)

09:30 - 10:30

Session 9

Chairpersons: Mariusz Gąsior, Michał Kasprzak

09:30 - 09:45

Clinical Outcomes of Left Main Coronary Artery PCI With Rotational Atherectomy

Sławomir Dobrzycki (Poland)

09:45 - 10:00

FLOzins for pREveNtion of Contrast inducEd nephropathy (FLORENCE) study. Rationale, protocol and current status of the FLORENCE study.

Piotr Niezgoda (Poland)

10:00 - 10:15

Coronary sinus reducer - an alternative for patients with refractory angina

Maciej Lesiak (Poland)

10:15 - 10:30

Discussion

10:30 - 10:45

Break

10:45 - 12:00

Session 10

Chairpersons: Jacek Kubica, Grzegorz Grześk, Bogumił Ramotowski

10:45 - 11:00

Dual antithrombotic therapy with Dabigatran and Ticagrelor in patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation undergoing percutaneous coronary intervention. Rationale, protocol and current status of the ADONIS trial.

Miłosz Jaguszewski (Poland)

11:00 - 11:15

Repetitive use of LEvosimendan in Ambulatory Heart Failure patients. Rationale, protocol and current status of the LEIA-HF trial.

Agnieszka Tycińska (Poland)

11:15 - 11:30

Clinical outcomes of left atrial appendage occlusion in patients with previous intracranial or gastrointestinal bleeding: Insights from the LOGIC International Multicenter Registry

Gavino Casu (Italy)

11:30 - 11:45

Myocardial Perfusion and Coronary Physiology Assessment of Microvascular Dysfunction in Patients Undergoing Transcatheter Aortic Valve Implantation-Rationale and Design

Wojciech Wojakowski (Poland)

11:45 - 12:00

Discussion

12:00 - 12:15

Break

12:15 - 13:30

Session 11: The ELECTRA-SIRIO 2 investigators’ standpoints

Chairpersons: Andrzej Budaj, Eliano P. Navarese

Panelists: Piotr Adamski, Sławomir Dobrzycki, Mariusz Gąsior, Marek Gierlotka, Grzegorz Grześk, Miłosz Jaguszewski, Adam Kern, Wacław Kochman, Aldona Kubica, Jacek Kubica, Wiktor Kuliczkowski, Maciej Lesiak, Grzegorz Sobieszek, Agnieszka Tycińska, Wojciech Wojakowski, Marzenna Zielińska

12:15 - 12:30

Bentracimab — a breakthrough for patients treated with antiplatelet agents?

Piotr Adamski

12:30 - 12:45

Prolonged antithrombotic treatment after de-escalation of dual antiplatelet therapy in patients after acute coronary syndrome - which strategy should be applied?

Piotr Niezgoda

12:45 - 13:00

Extended antithrombotic therapy in patients with chronic coronary syndrome - which agent should be added to aspirin?

Małgorzata Ostrowska

13:00 - 13:15

Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome.

Julia M. Umińska

13:15 - 13:30

Discussion

13:30 - 13:45

Break

13:45 - 15:00

Session 12: ELECTRA-SIRIO 2 trial investigators session

Chairpersons: Piotr Adamski, Miłosz Jaguszewski, Wiktor Kuliczkowski

Panelists: Tomasz Białoszyński, Bartosz Czarniak, Jacek Gessek, Łukasz Graczykowski, Paweł Grzelakowski, Tomasz Hajdukiewicz, Artur Klecha, Agata Kosobucka-Ozdoba, Bartosz Krakowiak, Ewa Laskowska, Lidia Manelska, Piotr Michalski, Łukasz Pietrzykowski, Ewa Obońska, Karolina Obońska, Maciej Piasecki, Przemysław Podhajski, Jakub Ratajczak, Janusz Romanek, Grzegorz Skonieczny, Mateusz Sobota, Paweł Szymański, Przemysław Wilczewski

13:45 - 14:45

ELECTRA-SIRIO 2 z perspektywy ABM
Marceli Ragan

ELECTRA-SIRIO 2 z perspektywy sponsora - CM UMK
Teresa Mallek-Urbańska

ELECTRA-SIRIO 2 z perspektywy CRO
Przemysław Magielski

ELECTRA-SIRIO 2 z perspektywy głównego badacza
Jacek Kubica

14:45 - 15:00

Discussion

15:00

Closing remarks

Jacek Kubica (Poland)